Resources from the same session
95MO - Characteristics of patients with brain metastases from HER2-positive breast cancer
Presenter: Elena Laakmann
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
4MO_PR - HER2-low breast cancer: evolution from primary breast cancer to relapse.
Presenter: Federica Miglietta
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
96MO - A Risk Analysis of Alpelisib (ALP)-Induced Hyperglycemia (HG) Using Baseline Factors in Patients (pts) With Advanced Solid Tumors and Breast Cancer (BC): A Pooled Analysis of X2101 and SOLAR-1
Presenter: Jordi Rodon
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
LBA4 - Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase 1 trial
Presenter: Aditya Bardia
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA4, 95MO and 4MO_PR
Presenter: Hiroji Iwata
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: All Speakers
Session: Mini Oral session 2
Resources:
Webcast
LBA1 - 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature
Presenter: Annelie Johansson
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1 and 96MO
Presenter: Prudence Francis
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: All Speakers
Session: Mini Oral session 2
Resources:
Webcast